Drug Profile
ET 019002
Alternative Names: ET019002-T Cell Therapy; ET019002-T CellsLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Eureka Therapeutics
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Gene transference; Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma in China (IV, Infusion)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in USA (IV, Infusion)
- 13 Apr 2020 Phase-I clinical trials in Non-Hodgkin's lymphoma in China (IV), prior to April 2020 (Eureka Therapeutics pipeline, April 2020)